Dingell generic drug probe
Executive Summary
House Commerce/Oversight & Investigations Subcommittee plans to interview more than the 60 FDA employees it had initially targeted for questioning in its investigation into the agency's generic drug approval process. The subcommittee, chaired by Rep. Dingell (D-Mich.), expects to finish first round of interviews, including the 60 FDAers, during the week ending April 8. Dingell has said that the interviews are necessary due to the expansion of the generic drug approval inquiry launched last summer ("The Pink Sheet" March 20, p. 3).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.